Non-Opioid Pain Devices: The Extra Medicare Payment Behind the Sales Pitch

Non-opioid pain device Medicare payment includes a separate payment for qualifying devices used in ambulatory surgery centers. An ASC reimbursement specialist or device employee may see a gap between the qualifying device, the clinical evidence and what the center actually billed. If the sales pitch puts extra Medicare revenue at the center of the purchase, we follow that promise through to the product used and the claim it produced.

The Centers for Medicare & Medicaid Services’ implementation summary for calendar 2025 sets the temporary payment window from January 1, 2025, through December 31, 2027, for qualifying treatments in hospital outpatient departments and ambulatory surgery centers. The manufacturer’s role in a false Medicare claim can begin with advice its customer uses to prepare the bill.

How Does Reimbursement Work for Medical Devices?

Medicare generally includes the cost of implanted devices in the payment for the procedure or hospital stay. In an ambulatory surgery center, implanted prosthetic devices and implanted durable medical equipment are ordinarily packaged into the surgical payment unless an exception applies. A separate payment changes that economic arrangement: the center can receive payment for a qualifying product outside the procedure’s bundled rate.

That makes the payment route part of the purchasing conversation. The Centers for Medicare & Medicaid Services says paying separately for qualifying non-opioid products is intended to encourage their use and reduce opioid use disorder and overdose. A reimbursement presentation turns that policy into a sales argument: extra payment for the center that buys the device.

Device pass-through payments are another temporary exception to packaging, with their own category and payment conditions. The first question about the pitch is which payment route the seller is relying on.

The Clinical Evidence Behind the Extra Payment

The Centers for Medicare & Medicaid Services says qualifying medical devices have demonstrated through evidence that they reduce opioid usage in the postoperative setting. What the device demonstrated helps determine whether it qualifies for the extra payment. Taxpayers fund that incentive to reduce opioid use after surgery. Paying for an unsupported reimbursement promise defeats its purpose.

The study and the sales presentation tell different parts of the story. What product did the study evaluate, in what setting, and what did it find about opioid use? What did the sales team tell the surgery center that finding meant for reimbursement? Those questions connect the employee who knows the evidence to the employee who knows the promise made to the customer.

FDA authorization, Medicare coverage and payment are separate decisions. The Food and Drug Administration decides whether a device may be marketed. Medicare decides coverage and payment, including whether a qualifying product receives this additional payment. A sales pitch that points to authorization as its support still leaves the payment decision to explain.

What the Facility Actually Bills

The claim shows what the surgery center asked Medicare to pay for. The purchase record identifies the device it acquired, while the clinical record identifies what was used during the procedure. Those records let an insider connect the reimbursement promise to the health care actually delivered.

The manufacturer’s reimbursement instructions show which HCPCS code it told the customer to use. The submitted claim shows whether the customer followed that advice. Together with the product and clinical records, they show whether the description billed matches what the center supplied.

The Payment Cap Behind the Sales Projection

CMS’s implementation summary describes a ceiling based on the estimated average of 18% of the hospital outpatient payment for the service or group of services furnished with the treatment. To calculate that limit for each non-opioid drug or device, CMS said it would use the top five hospital outpatient procedures by volume. The procedure mix is part of the calculation, which matters when a reimbursement presentation turns the policy into a projected dollar return.

We compare that projection with the applicable payment determination and the surgery center’s payment record. The amount a seller quotes, the amount the facility bills and the amount Medicare pays are different entries in that comparison. An insider who knows where the quoted number came from can help explain how it reached the customer’s financial forecast.

The date of surgery also matters to the promised payment. A presentation used to sell a device and instructions used to bill for a later procedure may refer to different payment periods. We trace the version the surgery center received to the payment determination in effect for that care, including any pass-through status the seller invoked.

When the Sales Pitch and the Claim Part Company

Manufacturer coding advice was at issue in Semler Scientific‘s $29.75 million settlement over allegations that it caused and conspired to cause improper Medicare claims for peripheral arterial disease testing. This parallel comes from diagnostic testing, where a seller’s reimbursement advice also reached the customer’s bill. The Justice Department announced the settlement in September 2025.

In their complaint about Semler’s reimbursement advice, the whistleblowers alleged that Semler told a clinic it could bill for use of QuantaFlo under particular procedure codes. They also alleged that Semler told the clinic it could not put that advice in writing.

We expect a seller’s billing advice to withstand being written down. Here, the customer allegedly could use the advice to ask the government for money, but could not get it on paper. For an employee handling non-opioid device reimbursement, the parallel is the path from the manufacturer’s promise to the customer’s bill.

The Records an Insider Can Connect

In healthcare fraud, the records that matter connect the product, the representation and the government payment. A 2020 review in the Journal of Forensic and Investigative Accounting, A Forensic Accountant’s Guide to the Most Potent Federal Laws Used Against Healthcare Fraud, distinguishes reimbursement requests that misdescribe goods or services from claims that falsely represent compliance with payment conditions. Applied here, that means looking at both what the surgery center supplied and what it represented about qualification for the additional payment.

If you work in clinical affairs, you may know which findings the company used to support its reimbursement pitch. In sales or reimbursement, you may know who prepared the instructions and what customers were told about the product, code and payment. At the surgery center, you may know what was used during the procedure and what appeared on the bill. We bring those accounts together around the same care and the same claim.

We examine internal questions, responses and changes to customer instructions to understand who knew what when the representation reached the provider. A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

You Know What the ASC Was Promised

If you know how a non-opioid device’s clinical evidence became a promise of Medicare payment, speak to one of our Whistleblower Experts about that promise. We work beside you to build your strongest medical device whistleblower case from the evidence, the sales instructions and the surgery center’s claims. We find medical device whistleblower lawyers who understand Medicare reimbursement and remain your partners throughout the case.